U.S., Jan. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07317960) titled 'Phase I Study of PollenVax in Patients With Mugwort Pollen-Induced Allergic Rhinitis' on Dec. 19, 2025.
Brief Summary: This Phase I randomized, double-blind, placebo-controlled clinical trial evaluates the safety and tolerability of PollenVax, a novel recombinant allergen-based vaccine for allergen-specific immunotherapy, in adult patients with mugwort pollen-induced allergic rhinitis.
Study Start Date: Nov. 22, 2025
Study Type: INTERVENTIONAL
Condition:
Allergic Rhinitis Due to Artemisia Pollen
Intervention:
BIOLOGICAL: PollenVax
PollenVax is a recombinant allergen-based vaccine containing recombinant Artemisia pollen major a...